Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL

Jeffrey Lancet • 9 Jun 2020
EHA 2020
Acute Promyelocytic Leukemia Leukemia Rare Diseases All-trans retinoic acid Antibodies Arsenic trioxide Gemtuzumab ozogamicin

Jeffrey Lancet, MD, of H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, reports results from a Phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk acute promyelocytic leukemia (APL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jeffrey Lancet

The role of transfusion support in older patients with AML no longer receiving active therapy
1:39
The role of transfusion support in older patients with AML no longer receiving active therapy
Jeffrey Lancet • 6 May 2026
Post-remission therapy in older adults with newly diagnosed AML and when to consider transplant
2:44
Post-remission therapy in older adults with newly diagnosed AML and when to consider transplant
Jeffrey Lancet • 6 May 2026
Barriers community oncologists may face when implementing ASH guidelines in older patients with AML
2:52
Barriers community oncologists may face when implementing ASH guidelines in older patients with AML
Jeffrey Lancet • 6 May 2026
Deciding whether an older patient with AML is a suitable candidate for antileukemic therapy
2:13
Deciding whether an older patient with AML is a suitable candidate for antileukemic therapy
Jeffrey Lancet • 6 May 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals